We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Are 'Reverse Payments' Becoming More Reasonable?

Law360 (March 30, 2009, 12:00 AM EDT) -- Over the last several years, competition between branded and generic drugs have become an increasingly important focus for U.S. antitrust authorities and private antitrust plaintiffs.

One hot button issue in this area has been patent settlements between branded and generic competitors in which the branded company pays the generic substantial sums and the generic agrees to delay market entry.

The new administration and Congress have expressed concern that reverse payments have caused generic equivalents of branded drugs to stay off the market, thereby delaying the entry...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.